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Translationally-Controlled Tumor-associated Protein (TCTP) has been discovered in 
1983 in mouse erythroleukemia cells. Over the years it became evident that TCTP is an 
important player in a number of basic cell physiology events in cancer, embryo 
development, cell cycle, apoptosis, proliferation, growth, stress response, allergy, gene 
regulation and heat-shock response. However, despite the nearly three decades of 
research, we only start to understand the role of TCTP in physiology of animal and plant 
embryo development as well as in numerous pathologies through its participation in cell 
cycle, proliferation and growth regulation. The exact roles of TCTP in many complex 
cellular processes still remain a mystery. One of the key questions in cancer research is 
the role of TCTP in tumor reversion, the rare event leading to tumor regression and a 
“miraculous” cure; is TCTP involved in gene regulation or rather modification of the 
cytoskeleton of cancer cells during this process?  It seems plausible that a novel type of 
posttranslational modification of TCTP, namely SUMOylationby regulating its nuclear 
localization and/or its association with the centrosomes, both featured in this issue, are 
responsible for some of the TCTP functions in normal and cancer cells. From the 
presented in this issue a very comprehensive and up to date reviews on TCTP functions it 
clearly transpires that TCTP has a potential to be a crucial target for anti cancer therapies. 
However, more research on the regulation of TCTP and its involvement in various 
molecular and cellular pathways and its association with subcellular structures is needed 
for the improvement of our understanding of this oncogene and development of novel 
TCTP-targeted cancer therapies. We hope that our special issue on TCTP in BRI will 
participate in stimulation of scientific research in this field.  
 
